Clinical efficacy and cost-effectiveness of mepolizumab for COPD with type 2 inflammation.
Saved in:
| Title: | Clinical efficacy and cost-effectiveness of mepolizumab for COPD with type 2 inflammation. |
|---|---|
| Authors: | Buendía JA; Research group in Pharmacology and Toxicology, Department of Pharmacology and Toxicology, University of Antioquia, Medellín, Colombia. jefferson.buendia@gmail.com., Guerrero Patiño D; Research group in Pharmacology and Toxicology, Department of Pharmacology and Toxicology, University of Antioquia, Medellín, Colombia., Muñoz Mejia O; Universidad CES, Medellin, Colombia., Celis Preciado C; Pulmonary Unit, Internal Medicine Department, Hospital Universitario San Ignacio, Bogota, Colombia. |
| Source: | BMC pulmonary medicine [BMC Pulm Med] 2026 Jan 07; Vol. 26 (1). Date of Electronic Publication: 2026 Jan 07. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: BioMed Central Country of Publication: England NLM ID: 100968563 Publication Model: Electronic Cited Medium: Internet ISSN: 1471-2466 (Electronic) Linking ISSN: 14712466 NLM ISO Abbreviation: BMC Pulm Med Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
| ISSN: | 1471-2466 |
|---|---|
| DOI: | 10.1186/s12890-025-04099-6 |
